A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer

被引：0
|
作者：
Lana E Kandalaft
Cheryl L Chiang
Janos Tanyi
Greg Motz
Klara Balint
Rosemarie Mick
George Coukos
机构：
[1] University of Pennsylvania,Ovarian Cancer Research Center
[2] University of Pennsylvania,Department of Biostatistics and Epidemiology, Perelman School of Medicine
来源：
Journal of Translational Medicine | / 11卷
关键词：
Recurrent ovarian cancer; Immunotherapy; Tumor vaccine; HOCl; Bevacizumab; Cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
    Kandalaft, Lana E.
    Chiang, Cheryl L.
    Tanyi, Janos
    Motz, Greg
    Balint, Klara
    Mick, Rosemarie
    Coukos, George
    JOURNAL OF TRANSLATIONAL MEDICINE, 2013, 11
  • [2] Vaccination with Dendritic Cells Pulsed with Novel Autologous Oxidized Whole Tumor Lysate Induced Anti-Tumor Immunity in Recurrent Ovarian Cancer Patients
    Tanyi, Janos L.
    Kandalaft, Lana
    Chiang, Cheryl L.
    Powell, Daniel J.
    Coukos, George
    REPRODUCTIVE SCIENCES, 2013, 20 (S3) : 85A - 85A
  • [3] A phase I clinical trial of autologous tumor lysate pulsed human dendritic cell vaccine in patients with colorectal carcinoma
    Wan, Tao
    Fu, Qiang
    Chen, Guoyou
    Jiang, Yingming
    Wu, Yanfeng
    Cao, Xuetao
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 903 - 904
  • [4] A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer
    Chang, AE
    Redman, BG
    Whitfield, JR
    Nickoloff, BJ
    Braun, TM
    Lee, PP
    Geiger, JD
    Mulé, JJ
    CLINICAL CANCER RESEARCH, 2002, 8 (04) : 1021 - 1032
  • [5] A phase I clinical trial in patients with newly diagnosed glioblastoma vaccinated with autologous dendritic cells pulsed with autologous tumor lysate.
    Boynton, A. L.
    Prins, R.
    Bosch, M.
    Yang, M.
    Odesa, S. K.
    Khan-Farooqi, H.
    Cloughesy, T.
    Liau, L.
    CYTOTHERAPY, 2006, 8
  • [6] Vaccination with dendritic cells pulsed with autologous oxidized whole tumor lysate induced strong and long-lasting anti-tumor immunity in recurrent ovarian cancer patients
    Chiang, Cheryl L-L
    Kandalaft, Lana
    Tanyi, Janos
    Mantina, Gina
    Zsiros, Emese
    Powell, Daniel J.
    Coukos, George
    CANCER RESEARCH, 2012, 72
  • [7] A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside
    Chiang, Cheryl Lai-Lai
    Kandalaft, Lana E.
    Tanyi, Janos
    Hagemann, Andrea R.
    Motz, Gregory T.
    Svoronos, Nikolaos
    Montone, Kathleen
    Mantia-Smaldone, Gina M.
    Smith, Lori
    Nisenbaum, Harvey L.
    Levine, Bruce L.
    Kalos, Michael
    Czerniecki, Brian J.
    Torigian, Drew A.
    Powell, Daniel J., Jr.
    Mick, Rosemarie
    Coukos, George
    CLINICAL CANCER RESEARCH, 2013, 19 (17) : 4801 - 4815
  • [8] A PHASE I TRIAL OF VACCINATION WITH AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE DERIVED FROM AN ALLOGENEIC GLIOBLASTOMA STEMLIKE CELL LINE FOR PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA
    Hu, Jethro
    Rudnick, Jeremy
    Wheeler, Christopher
    Mazer, Mia
    Wang, HongQiang
    Black, Keith
    Yu, John
    NEURO-ONCOLOGY, 2018, 20 : 4 - 4
  • [9] Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
    Kandalaft, Lana E.
    Powell, Daniel J., Jr.
    Chiang, Cheryl L.
    Tanyi, Janos
    Kim, Sarah
    Bosch, Marnix
    Montone, Kathy
    Mick, Rosemarie
    Levine, Bruce L.
    Torigian, Drew A.
    June, Carl H.
    Coukos, George
    ONCOIMMUNOLOGY, 2013, 2 (01):
  • [10] In vitro assessment of the efficacy of a tumor vaccine with autologous, tumor-lysate pulsed dendritic cells
    Galambos, P
    Schnurr, M
    Nienborg, H
    Siegmund, B
    Bidlingmaier, M
    Endres, S
    Eigler, A
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 114 (01) : 217 - 217
12345